Invention Grant
- Patent Title: Recombinant viral vector, immune composition containing same, and use thereof
-
Application No.: US17280803Application Date: 2019-06-12
-
Publication No.: US12195517B2Publication Date: 2025-01-14
- Inventor: Jianqing Xu , Yang Huang , Xiaoyan Zhang , Lu Wang , Mingquan Gao , Jiahao Sun
- Applicant: VACDIAGN BIOTECHNOLOGY CO., LTD
- Applicant Address: CN Suzhou
- Assignee: VACDIAGN BIOTECHNOLOGY CO., LTD
- Current Assignee: VACDIAGN BIOTECHNOLOGY CO., LTD
- Current Assignee Address: CN Suzhou
- Agency: Christensen O'Connor Johnson Kindness PLLC
- International Application: PCT/CN2019/090877 WO 20190612
- International Announcement: WO2020/062930 WO 20200402
- Main IPC: C07K14/73
- IPC: C07K14/73 ; A61K39/00 ; A61K39/02 ; A61K39/12 ; A61K39/145 ; A61K39/245 ; A61P31/04 ; A61P31/16 ; A61P31/20 ; A61P31/22 ; A61P35/00 ; C07K14/005 ; C12N7/00 ; C12N15/86

Abstract:
The present invention provides a recombinant viral vector, an immunogenic composition containing the same, and the use thereof. The recombinant viral vector comprises a polynucleotide encoding a fusion peptide of CD4 helper T cell epitopes, the epitope fusion peptide comprising a cytomegalovirus epitope and/or an influenza virus epitope. The epitope fusion peptide and the recombinant viral vector provided by the present invention can improve the level of cellular immune response to a target immunogen, particularly to a weak immunogen, and overcome the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen. The products of the present invention are suitable for enhancing the efficacy of vaccines.
Public/Granted literature
- US20220002750A1 RECOMBINANT VIRAL VECTOR, IMMUNE COMPOSITION CONTAINING SAME, AND USE THEREOF Public/Granted day:2022-01-06
Information query